PAH & Scleroderma Medication Study

Trial Objective

Investigational Drug for Scleroderma-associated PAHResearchers are trying to determine if Tecfidera® (generic: dimethyl fumarate or DMF) is effective in the treatment of pulmonary arterial hypertension (PAH) associated with systemic sclerosis, which is commonly called scleroderma.

Tecfidera decreases the chemical activity triggered by inflammation. The drug has been FDA approved for treating multiple sclerosis, but is considered experimental for systemic sclerosis. The goal of this study is to determine if Tecfidera can help improve patients’ mobility and oxygen levels.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

Adults who have PAH (pulmonary arterial hypertension) associated with scleroderma.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

6 visits over 40 weeks

This study will last a total of 40 weeks, including a four week screening period, 24 weeks medication period and a 12 week follow-up period. During this time, there will be six visits to the clinic and two check-in phone calls.



Compensation

Provided

Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos
303.398.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health (NIH)

Principal Investigators


Request More Information

*
*
*
*